Jun. 21 at 10:24 PM
$ALNY 's share price & valuation has dropped so meaningfully since Thanksgiving, we now include ALNY in our non-BP trackers.
Analysts forecast ALNY to generate slightly more revenues over the next 5 years as
$ARGX , albeit at slightly lower gross margins due to ALNY's royalty obligation to
$SNY , yet ARGX's enterprise value is 36% higher. Analysts forecast both bio's 10 year revenues to be within 3%.
The attached graph visualizes how analysts believe both have virtally identical revenue profiles yet because of the disconnect in valuation, ALNY trades at meaningfully lower multiples.
We're only sharing an observation. This is not investment advice. There may be very good reasons for the disconnect. If anyone can share a perspective, it would be genuinely appreciated.
$XBI $IBB
